Hiru Corporation

Hiru Corporation

January 11, 2011 15:45 ET

Jiangxi Shaungshi (HIRU) Obtains Approval for 4 New Veterinary Products in the Chinese Market

HENDERSON, NEVADA--(Marketwire - Jan. 11, 2011) - Hiru Corporation (PINK SHEETS:HIRU) (www.hirucorporation.com) subsidiary Jiangxi Shaungshi AHP reports that 4 of the company products passed China government testing.

Jiangxi Shaungshi AHP received report from the Chinese Ministry of Agriculture for the company's four (4) products submitted for government testing. All 4 products had passed through examination and inspection of the Ministry and have obtained approval documents, meeting the mandatory GB standards. GB standards represent the Chinese national standards, issued by the Standardization Administration of China (SAC), the Chinese National Committee of the ISO and IEC (International Electrotechnical Commission).

The 4 approved veterinary products are:

  • Mixed Clear Sense of Blood (Vet. Drug# 14021617);
  • Cough Litai (Vet. Drug# 140213026);
  • Lai Pusen Injection (Vet. Drug# 140212764);
  • Hunganduzun (Vet. Drug# 140212548).

The company expects these products to enhance the company's already extensive portfolio, and start producing and marketing these products with the Chinese farmers shortly. The company R&D has been hard at work and the company expects to bring more products onto the Chinese market.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation's control. In addition to those discussed in Hiru Corporation's press releases, public filings, and statements by Hiru Corporation's management, including, but not limited to, Hiru Corporation's estimate of the sufficiency of its existing capital resources, Hiru Corporation's ability to raise additional capital to fund future operations, Hiru Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contact Information